India  
 
NewsR.in

United States: Updates On Aflibercept BPCIA Litigation - Goodwin Procter LLP

Mondaq Tuesday, 26 March 2024
As we previously reported, on January 11, 2024, Regeneron Pharmaceuticals, Inc. ("Regeneron") filed a motion seeking to establish a multi-district litigation ("MDL")...
0
shares		ShareTweetSavePostSend
 

You Might Like


Related news from verified sources

United States: Biocon Settles With Bayer And Regeneron, Securing Canada Market Entry Date For Aflibercept Biosimilar - Goodwin Procter LLP

 On March 4, Biocon Biologics Ltd. announced it has signed a settlement agreement with Bayer Inc. and Regeneron Pharmaceuticals, Inc. regarding YESAFILI, Biocon's...
Mondaq

United States: In Re Sears Hometown And Outlet Stores, Inc. Stockholder Litigation, 2024 WL 262322 (Del. Ch. Jan. 24, 2024) - Goodwin Procter LLP

 Until recently, Delaware law offered no clear standard of review for a controller's exercise of stockholder voting power.
Mondaq